Where does Oxyrane UK Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Oxyrane UK Limited ranks #18,997 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Oxyrane UK Limited hold?

Oxyrane UK Limited holds 15 US utility patents granted between 2015 and 2022, spanning 7 technology areas.

What is Oxyrane UK Limited's Innovation Score?

Oxyrane UK Limited has an Innovation Score of 34.7 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Oxyrane UK Limited focus on?

Oxyrane UK Limited's top technology area is C12Y (Enzymes) with 14 patents, ranking #183 of 1,675 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Oxyrane UK Limited's patent grant rate increasing or decreasing?

Oxyrane UK Limited's recent grant velocity is -75% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Oxyrane UK Limited's patents?

Oxyrane UK Limited's patents average 24.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Oxyrane UK Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Oxyrane UK Limited

USPTO PatentsView assignee record - 15 granted patents across 7 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Y (Enzymes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Oxyrane ranks #18,997 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 7 technology areas.

#18,997
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.7/100): 24.0
avg claims per patent: -75%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18997 · Foreign Corporation #18,997 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,997/49,997
PHOTO-FINISH Otago Innovation
CPC-NARROW C12Y · 7 areas
INNOV-THIN 34.7/100
CLAIMS-DENSE 24.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -75% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Otago Innovation Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Oxyrane’s 34.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (28%) Velocity 1.3 pts (4%) Breadth 9.4 pts (27%) Claim depth 14.4 pts (41%)

Qualcomm Incorporated · highest

85
Oxyrane UK · this assignee

35
3D Lighting… · lowest

7

What this shows Oxyrane's Innovation Score is 34.7/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Oxyrane?

Each dot is one of Oxyrane’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Oxyrane’s own 24.0 claims/patent is ABOVE the 15.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Oxyrane vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Oxyrane's grants concentrate

Oxyrane UK Limited is a focused PatentsView assignee: 7 CPC subclasses with 93.3% of grants classified under C12Y (Enzymes). Peak complete grant year is 2016 (3 grants) versus a trough of 1 in 2020. By volume, Oxyrane sits between Otago Innovation Ltd. and Pallmann Maschinenfabrik GmbH & Co. KG.

Oxyrane's three-year grant acceleration

Oxyrane UK Limited shows 1 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Otago Innovation

15
Otter ai

15
Outerwall

15
Outset Medical

15
Pablo AIR

15
Pacific GAS AND E…

15
Pacificedge

15
Pallmann Maschine…

15
Oxyrane UK ◀

15

What this shows Oxyrane holds 15 patents at rank #18,991, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Oxyrane

By rank, the assignees closest to #18,991 in granted patent volume.

Leaders in C12Y (Enzymes)

Other assignees with the most granted patents in Oxyrane's primary technology class.

Oxyrane's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Oxyrane UK Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	13.3%
2016	3	20.0%
2017	2	13.3%
2018	2	13.3%
2019	3	20.0%
2020	1	6.7%
2021	1	6.7%
2022	1	6.7%

Which technologies does Oxyrane UK Limited patent most?

C12Y - Enzymes 14

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 14

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 13

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

C07K - Peptides 10

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Oxyrane UK Limited's patent record in context - here's where to go next.

Oxyrane UK Limited's lead technology class is C12Y (Enzymes), 93.3% of its portfolio - see every assignee active in that class. Explore C12Y
Ranked #18,997 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Oxyrane UK Limited against Otago Innovation Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.